|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12Q 1/68 | (2018.01) |
| C12Q 1/6886 | (2013.01) | ||
| C12Q2600/106 | (2013.01) | ||
| C12Q2600/158 | (2013.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Number of the document | 3551761 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16809752.5 |
| Date of filing the European patent application | 2016-12-07 | |
| (97) | Date of publication of the European application | 2019-10-16 |
| (45) | Date of publication and mention of the grant of the patent | 2022-03-16 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2016/080056 |
| Date | 2016-12-07 |
| (87) | Number | WO 2018/103834 |
| Date | 2018-06-14 |
| (72) |
PRAT APARICIO, Aleix , ES
CORTÉS CASTÁN, Javier , ES
LLOMBART CUSSAC, Antonio , ES
|
| (73) |
Fundació Privada Institut d'Investigació
Oncològica de Vall-Hebron ,
C/ Natzaret 115, 08035 Barcelona,
ES
Fundación Solti , C. Balmes 89 3º 7ª, 08008 Barcelona, ES Fundación para el Fomento de la Investigación Sanitaria y Biomedica de la comunitat Valenciana , Avda. Catalunya, 21, 46020 Valencia, ES Hospital Clínic de Barcelona , C. Villarroel 170, 08036 Barcelona, ES |
| (54) | HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY |
| HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY |